152 related articles for article (PubMed ID: 27905324)
1. Primary neuroendocrine carcinoma of the breast A single Center experience and review of the literature.
Locurto P; Antona AD; Grillo A; Ciulla A; Martorana S; Cipolla C; Graceffa G; Vieni S
Ann Ital Chir; 2016 Nov; 87():. PubMed ID: 27905324
[TBL] [Abstract][Full Text] [Related]
2. [Intracystic papillary carcinoma of the breast: report of three cases].
El mazghi A; Bouhafa T; Loukili K; El kacemi H; Lalya I; Kebdani T; Hassouni K
Pan Afr Med J; 2014; 18():207. PubMed ID: 25419333
[TBL] [Abstract][Full Text] [Related]
3. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
4. [Incidence of axillary recurrence after a negative sentinel lymph node result in early stages of breast cancer: a 5-year follow-up].
Ruano Pérez R; Ramos Boyero M; García-Talavera Fernández JR; Ramos Grande T; González-Orús JM; Gómez-Caminero López F; García Macias MC; Martín de Arriba A
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):173-7. PubMed ID: 23067685
[TBL] [Abstract][Full Text] [Related]
5. [Primary neuroendocrine tumors of the breast: a retrospective study of 21 cases and literature review].
Feki J; Fourati N; Mnif H; Khabir A; Toumi N; Khanfir A; Boudawara T; Amouri H; Daoud J; Frikha M
Cancer Radiother; 2015 Aug; 19(5):308-12. PubMed ID: 26215367
[TBL] [Abstract][Full Text] [Related]
6. Management of neuroendocrine carcinomas of the breast: A rare entity.
Yildirim Y; Elagoz S; Koyuncu A; Aydin C; Karadayi K
Oncol Lett; 2011 Sep; 2(5):887-890. PubMed ID: 22866145
[TBL] [Abstract][Full Text] [Related]
7. [Breast carcinoma with predominant neuroendocrine differentiation].
Frachon S; Pasquier D; Treilleux I; Seigneurin D; Ringeisen F; Rosier P; Bolla M; Boutonnat J
Ann Pathol; 2004 Jun; 24(3):278-83. PubMed ID: 15480266
[TBL] [Abstract][Full Text] [Related]
8. Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.
Angarita FA; Rodríguez JL; Meek E; Sánchez JO; Tawil M; Torregrosa L
World J Surg Oncol; 2013 Jun; 11():128. PubMed ID: 23734899
[TBL] [Abstract][Full Text] [Related]
9. Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer.
Kuo SH; Chen CL; Huang CS; Cheng AL
Anticancer Res; 2000; 20(3B):2219-22. PubMed ID: 10928181
[TBL] [Abstract][Full Text] [Related]
10. Primary neuroendocrine carcinoma breast: our experience.
Suhani ; Ali S; Desai G; Thomas S; Aggarwal L; Meena K; Kumar J; Jain M; Tudu SK
Breast Dis; 2014; 34(3):95-9. PubMed ID: 24004513
[TBL] [Abstract][Full Text] [Related]
11. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine carcinoma of the breast--diagnostic and clinical implications.
Watrowski R; Jäger C; Mattern D; Horst C
Anticancer Res; 2012 Nov; 32(11):5079-82. PubMed ID: 23155283
[TBL] [Abstract][Full Text] [Related]
13. Primary neuroendocrine small cell carcinoma of the breast.
Samli B; Celik S; Evrensel T; Orhan B; Tasdelen I
Arch Pathol Lab Med; 2000 Feb; 124(2):296-8. PubMed ID: 10656743
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine carcinomas of the breast.
Rovera F; Masciocchi P; Coglitore A; La Rosa S; Dionigi G; Marelli M; Boni L; Dionigi R
Int J Surg; 2008; 6 Suppl 1():S113-5. PubMed ID: 19167937
[TBL] [Abstract][Full Text] [Related]
15. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
Curigliano G; Criscitiello C
J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
[TBL] [Abstract][Full Text] [Related]
16. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
[TBL] [Abstract][Full Text] [Related]
17. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Han W; Han MR; Kang JJ; Bae JY; Lee JH; Bae YJ; Lee JE; Shin HJ; Hwang KT; Hwang SE; Kim SW; Noh DY
BMC Cancer; 2006 Apr; 6():92. PubMed ID: 16608533
[TBL] [Abstract][Full Text] [Related]
18. Primary neuroendocrine tumors of the breast: two case reports and review of the literature.
Hejjane L; Oualla K; Bouchbika Z; Bourhafour M; Lhlou Mimi A; Boubacar E; Benider A; Benbrahim Z; Aarifi S; Mellas N
J Med Case Rep; 2020 Mar; 14(1):41. PubMed ID: 32156307
[TBL] [Abstract][Full Text] [Related]
19. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
20. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Abdel-Fatah TM; McArdle SE; Johnson C; Moseley PM; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Br J Cancer; 2014 May; 110(10):2450-61. PubMed ID: 24755885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
